CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
BCNU +4 moredrug
Likely dose
BCNU 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01141712
NCT01141712Phase 2Completed
CompareCT.gov

High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN #0803)

Medical College of Wisconsin·interventional·Posted Jun 10, 2010·Updated Jan 4, 2023

In Brief

A Phase 2 clinical trial evaluating Autologous transplant, BCNU, and 3 other interventions for Lymphoma and HIV. Completed, enrolled 43 participants across 16 sites.

Detailed Summary

This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, HIV
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 10, 2010
Enrollment StartApr 1, 2010
Primary CompletionMay 1, 2015
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 16.1 years ago

Interventions

Autologous transplantprocedure

Participants will receive the BEAM conditioning regimen followed by autologous HCT.

BCNUdrug

Participants will receive BCNU 300 mg/m\^2 Day -6

Etoposidedrug

Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2

Cytarabinedrug

Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2

Melphalandrug

Participants will receive Melphalan 140 mg/m\^2 Day -1